The DPP7 Knockout A-549 Polyclonal Cells represent a polyclonal population of CRISPR/Cas9-edited A-549 cells that carry targeted disruption of the DPP7 gene, resulting in a loss-of-function model for dipeptidyl peptidase 7. This polyclonal knockout cell mixture is derived from the A-549 lung epithelial carcinoma cell line and provides a heterogeneous genetic background suitable for studying DPP7-dependent processes in a cancer-relevant context without selection for clonal isolates. The knockout cells have been verified for DPP7 ablation using standard molecular techniques and serve as a versatile research tool for functional genomics and protease biology.
The host cell line A-549 is a widely employed model of human alveolar basal epithelial cells, originally isolated from a 58-year-old male with lung carcinoma. These adherent epithelial cells are extensively characterized and frequently utilized in studies of lung cancer biology, inflammatory responses, and epithelial barrier function. Their robust growth properties and well-documented signaling networks make them an ideal platform for generating gene-edited derivatives, enabling detailed mechanistic investigations within a physiologically relevant pulmonary epithelial background.
DPP7 encodes a lysosomal serine protease that functions as a dipeptidyl peptidase, cleaving N-terminal dipeptides from peptide substrates with a preference for proline or alanine at the P1 position. In the cellular context, DPP7 activity is regulated by pro-inflammatory cytokines and cellular stress signals, and it interacts with lysosomal proteases, extracellular matrix proteins, and other dipeptidyl peptidases to coordinate protein catabolism. It processes peptide substrates that are subsequently loaded onto MHC class I molecules via the transporter associated with antigen processing (TAP), thereby contributing to antigen presentation. Additionally, DPP7 participates in collagen metabolism and apoptotic signaling through the generation of specific collagen fragments and modulation of apoptotic pathways.
In the A-549 background, disruption of DPP7 is expected to impair the proteolytic generation of peptide ligands for MHC-I, potentially reducing surface MHC-I expression and altering immune surveillance mechanisms relevant to lung carcinoma. The loss of DPP7 may also disrupt collagen processing and apoptotic signaling, influencing tumor cell survival and migration. This polyclonal knockout model thus permits investigation of DPP7’s role in protein turnover, antigen processing, and the tumor microenvironment, offering insights into how impaired dipeptidyl peptidase activity impacts cancer cell immunogenicity and disease progression.
The DPP7 Knockout A-549 Polyclonal Cells are suitable for diverse research applications, including functional characterization of DPP7 in lung cancer, identification of protease substrates, drug target validation for immune modulation, and mechanistic studies of antigen processing. Compatible assays include Western blotting and RT-qPCR for DPP7 expression, protease activity measurements, immunofluorescence localization, flow cytometric analysis of MHC-I surface levels, apoptosis assays, and cell migration experiments. For product inquiries or technical support, please contact Ascent Research.
